A 3D printed talus can save a patient from an ankle fusion

Orthopedic Surgeon Dr. Mark Myerson Pioneers Unique New Approach to Treating Avascular Necrosis of the Talus (MDMercy)
(Baltimore, MD) — The talus is the part ankle that allows the foot to move in all different directions. High impact injuries like falls, or traffic accidents can cause the talus bone to be fractured, and a high percentage of these injuries result in avascular necrosis (AVN)—the death of the bone. In a first-of-its-kind procedure using 3D printing technology, internationally renowned orthopedic surgeon Dr. Mark Myerson, Director, The Institute for Foot and Ankle Reconstruction at Mercy Medical Center, explains how a talus replacement, tailored to the patient’s specific dimensions, can result in a “life-changing experience” for the patient.
“The talus has limited blood circulation, and when it is fractured, that blood circulation is commonly lost. The result is avascular necrosis (AVN). Over time the bone will crumble and collapse, like a squashed orange. You’re left with a flattened, painful and arthritic ankle. When you remove the dead bone from the ankle you are left with a massive hole. The treatment offered to patients to date has been to fuse the heel to the leg (the tibia) and these results are particularly poor. The patient is left with a stiff ankle without any movement at all. However, we have a new method of treatment which is truly unique,” Dr. Myerson said.
The patient’s healthy ankle is imaged by a CAT scan; then using computer engineering, the image is reversed and becomes a blueprint for creating the new talus, “to be a match for the abnormal talus with AVN which is removed. 3D printing technology (provided by 4Web Medical) is used to create a new talus to take the place of the dead bone,” Dr. Myerson said.
Several trial implants, made of plastic, are provided to be inserted to determine the best fit. “Once we decide on the one that fits, we then select the appropriate matched size to insert in to the patient,” Dr. Myerson said. The final prosthesis to be inserted is made of cobalt and chrome.
“This is not an ankle replacement. An ankle replacement may be appropriate for a patient with ankle arthritis, but it cannot be done with patients with avascular necrosis of the talus,” Dr. Myerson explained.
Patients who receive the 3D-printed talus replacement may regain up to 75 percent of normal ankle function.
“If you have a fusion, there is no movement. The talus replacement allows for the movement of both the ankle and subtalar joints which make moving the foot up and down and side to side possible. The talus replacement helps move these joints because it replaces both surfaces. The final result is truly unbelievable, the mobility it affords the patient, enhancing their quality of life. I’ve been practicing orthopedic surgery of the foot and ankle for 32 years and it is rare that something like this comes along that help patients in this way,” Dr. Myerson said.

Dan Collins, Senior Director of Media Relations
Email: [email protected] Office: 410-332-9714 Cell: 410-375-7342

Read More

Hiring is Better with Retained

I used to think Contingency Recruiting was the best way to find talent for your company… but I’ve changed my mind.

I have been on all sides of the table in Orthopedic companies.  The Contingency process is broken. The fundamental flaw is that…   your goals of hiring the best talent and the goals of a Contingency Recruiter are simply not aligned.
Let me explain.

 Contingency = low commitment

The bulk of recruiting done in Ortho/Spine is with Contingency Recruiting.  It’s easy and LOW COMMITMENT for both sides. Your Contingency Recruiter is a nice person and seems to be on top of things.  When you get a flood of resumes coming in, it feels like progress towards that great hire. Wrong. You are being misled into believing that you are seeing good talent.  You are not.
5 shortcomings of using a Contingency Recruiter.
1) Lower Quality Talent
A Contingency search will not bring you the best talent available.  Contingency Recruiters target active candidates, but the best candidates are typically passive.  Active candidates are unemployed or about to be unemployed.  Passive candidates are currently doing a great job at another company with no plans of making a move. They are well-paid star performers and are not looking to make a move.  You want to see passive candidates.
2) Less Commitment to Your Search
Contingency Recruiters will only give you a tiny fraction of their time. Contingency Recruiters do not have time to conduct a thorough search.  Contingency recruiters must be first in order to get paid.  It is a race against the other Contingency Recruiters who are trying to fill the same position. They will flame out quickly on your search.
3) Less Vetting
Contingency Recruiters don’t have time to do a deep screen of the candidates who they are presenting. It’s a numbers game and they are working Contingency searches at 10-30 companies at the same time.  How about this resume? Ok, then how about this resume?  Ok, then…   The net result is that you are getting lower quality resumes from Contingency Recruiters because they don’t have time to vet the candidates because it’s a time race among the Contingency Recruiters.
4) Not Objective
Contingency Recruiters will coach or prep candidates for the interview at your company, so often you are not seeing the real person. They are biasing their candidate over the other Contingency Recruiters candidates in order to win the race.
5) Lack of Loyalty 
Contingency Recruiters will present your candidate to other companies making you compete over the candidate and essentially undermining the process. I have been that hiring manager only to lose a good candidate for another company because the recruiter shopped him/her around at the same time.
 

 Retained = high commitment
 
The less traveled recruiting method used in Ortho/Spine is Retained Recruiting.  The goals of your Retained Recruiter are aligned with yours. It is based on a HIGH COMMITMENT relationship.  I believe that the Retained approach is better for your key positions if you must find a key person who will have a significant impact on your company – a transformational position.  And I believe that Retained approach is better for smaller companies where each position counts.

8 advantages of using a Retained Recruiter.
1) Higher Quality Talent
A Retained Recruiter doesn’t go after the job seekers (active), they look for the best candidates (passive) who are currently doing a great job at your competitor.
2) More Commitment to Your Search
A Retained Recruiter will allocate a large portion of their time to your search.  Retained Recruiters know that you are serious because you have paid a retainer up front and they are exclusive to your search.  Since you have skin in the game, the Retained Recruiter is committed to your success.  The Retained Recruiter will attack your search with laser focus.

3) Careful Vetting
Retained Recruiters invest the time to “know” the candidates who are presented.  You will see fewer candidates, but much higher quality candidates.
4) Totally Objective
Retained Recruiters will never coach or prep candidates for the interview. In fact, they will be careful to not dress up the candidates. And an even more refreshing aspect of the retained process is that the retained recruiter will highlight warts and flaws of each candidate because he wants you to make the best choice among the lot.
5) Loyalty
Retained Recruiters will never present your candidate to another company.  You will not see candidates who are being shopped around to other companies.  The Retained process is a partnership with your company. He wants you to find the best.
6) Less Noise
With a Retained search, you only have to deal with a single recruiter.  Also, you will have fewer fully vetted candidates to review. With a Contingency search, the hiring manager and HR must deal with multiple Contingency Recruiters simultaneously and a flood of resumes coming in.
7) Longevity of Hire
I cannot prove this with stats, but anecdotally I know that Retained hires stick longer than Contingency hires.  The quality of the search process and vetting results in more career longevity.

8) Cost
Surprisingly, a Retained search will cost the same or just a bit more than a Contingency search even with the upfront retainer payment.

 

Read More

Mazor Robotics wins a $42M partnership and equity deal with Medtronic

Mazor Robotics inks $42m deal with Medtronic (MassDevice)
Mazor Robotics (NSDQ:MZOR) said today that it inked a 2-phase deal with Medtronic (NYSE:MDT) for its robot-assisted spine surgery technology that includes a co-promotion agreement and an equity investment that could see Medtronic wind up with a 15% stake in the Israeli company for as much as $42 million.
Caesarea, Israel-based Mazor said the 1st phase of the deal calls for Medtronic to acquire 15 Mazor systems this year. It also makes Medtronic Mazor’s sole partner for developing and commercializing robot-assisted spine surgery devices; if both meet their milestones by the end of 2017, the deal is slated to progress to the 2nd phase. Mazor said its already working with Fridley, Minn.-based Medtronic on the development of “synergistic” spine products “and will begin working closely together to meet designated sales targets through a defined methodology for cooperation.”
The 2nd phase involves a 3-step equity investment by Medtronic, in which the world’s largest pure-play medtech maker would 1st pay $12 million for a 4% stake in Mazor. The 2nd tranche, triggered by Mazor achieving operational milestones, would see Medtronic acquire a 6% stake at the 20-day average share price for MZOR stock. In the 3rd tranche, triggered by the 2nd tranche and the execution of a global distribution agreement – but executed at Mazor’s discretion – Medtronic would buy another 5% stake, again at the 20-day MZOR average. Mazor said Medtronic can cap the 2nd and 3rd tranches at $20 million apiece.
“The structure of the commercial agreement features some very important points for our customers as well as our shareholders,” Mazor CEO Ori Hadomi said in prepared remarks. “New developments, such as synergistic implants, could generate new revenue streams for Mazor, beyond the anticipated growth in our current revenue streams from capital equipment, service agreements and disposables. The synergy between the organizations’ teams will potentially yield operational efficiency benefits for Mazor.”
Mazor said it plans to stay independent and will still market its Renaissance robot-assisted surgery platform.
MZOR shares jumped.

Read More

Two likely outcomes as Alphatec Spine winds down

ALPHATEC’S HOLE DEEPENS. WHAT’S NEXT?  (Orthopedics This Week)
Conditions at Alphatec have, apparently, reached the stage where a press release regarding the quarterly results is not considered necessary.
Nor, for that matter, is a call with Wall Street analysts to review the quarter.
On May 6, 2016 Alphatec Spine filed the required 10-Q financial report with the Securities and Exchange Commission (SEC). Normally, that would prompt both a press release and a call with analysts and institutional investors.
Not this time.
While management appears to have gone radio silent, rank and file Alphatec employees are lighting up anonymous web-based message boards with blistering critiques and dire warnings.
Comments like this one are being repeated in one form or another: “Pros: great benefits, good products and excellent people who work here. Cons: sales down, morale not good, no cash flow, no hiring in early 2016, not very positive work environment. Used to be better when DK was here.”
DK refers to Dirk Kuyper, CEO at Alphatec from 2007 to 2012.
Reading the tea leaves, Alphatec may be vacillating between two potential circumstances:

Debt holders have replaced equity owners as the company’s most important constituency and are putting together some form of recapitalization—with our without court assistance—likely without current management.
Or a buyer for Alphatec is trying to close the deal and a call with Wall Street will wait until that is wrapped up.

Reading Alphatec’s 10-Q
Alphatec’s March 2016 SEC filing is tough reading. No doubt the company’s attorneys urged management to disgorge every possible negative fact or possibility.
Here are the key points:

Sales for the three months ended March 31, 2016 fell 8% from the same period last year.
Operating earnings turned from a $1.1 million profit last year to a $3.7 million loss this year.
Net loss reached $6.6 million.
Cash at the end of the quarter was $7.8 million.
Total current liabilities at the end of the quarter were $130 million.
Total current assets at the end of the quarter were $100 million.

The following table illustrates how steadily Alphatec’s operations have deteriorated since 2013.
Source: Alphatec’s 10-Q filings with the Securities and Exchange Commission

First quarter sales declined each year since 2013/
Alphatec has reported an operating loss in 3 of the last 4 1st quarters.
Cash balances are now one-third of 2014 levels.
Current debts are now 30% more than current liabilities.

In its March filing with the SEC, management disclosed the depth of its financial distress saying, in effect, that the company could not meet its financial obligations this year without some form of help from investors.
“There is no assurance that we will be in compliance with the financial covenants of the Amended Credit Facility or the Facility Agreement in April 2016 or in the future” said Alphatec in its March 2016 10-Q filing. “If we have future defaults and we do not obtain waivers from MidCap or Deerfield they would have the right to call their respective debts due immediately, which would significantly impact our ability to continue as a going concern. We intend to pursue additional opportunities to raise additional capital through public or private equity offerings, debt financings, receivables financings or collaborations or partnerships with other companies to further support our planned operations. However, there is no assurance that we will be able to do so. Accordingly, as of March 31, 2016, there is substantial doubt about our ability to continue as a going concern through December 31, 2016.”
In short, investors, employees and other stakeholders are hanging on for whatever happens next and hoping that time has not finally run out for Alphatec.

Read More

First look at clinical results for Moximed's Atlas joint unloading device

ATLAS SYSTEM FOR OA PATIENTS: FIRST RESULTS (Orthopedics This Week)
The first data is out on the Atlas System, a unicompartmental joint unloading device for pre-arthroplasty knee osteoarthritis (OA) patients, developed by Moximed, Inc. As indicated in the May 9, 2016 news release, the data, “revealed that patients with the Atlas System experienced effective pain relief, regained range of motion, and returned to normal activity levels within several weeks. The Atlas System obtained CE Mark at the end of 2015, and the company is in the early phases of introducing the product to European customers.”
“We are seeing increasing numbers of younger patients with knee osteoarthritis who are looking for pain relief and the ability to get back to their active lifestyles,” explained Robert Smigielski, M.D., of the Carolina Clinic in Warsaw, Poland, and a team doctor for the Polish Olympic team. “The data from our study show that these patients could benefit from the Atlas System and its joint unloading and joint preserving approach.”
As indicated in the news release, “Data from a 26-patient prospective, multi-center study presented at ESSKA [European Society of Sports Traumatology, Knee Surgery & Arthroscopy] demonstrated that the Atlas System provides rapid, clinically effective pain relief and an excellent safety profile for patients with early knee OA in the pre-arthroplasty stage of their disease. WOMAC pain and functions scores improved from 53 ± 8 and 48 ± 17 at baseline to 17 ± 16 and 21 ± 17 at six months, respectively (lower scores represent improvement); 92% of patients experienced a clinically meaningful improvement on their WOMAC pain score, defined as a 10-point absolute improvement. Knee Society Pain and Function Scores improved from 62 ± 15 and 73 ± 14 at baseline to 91 ± 10 and 98 ± 4 at six months, respectively. Patients regained baseline range of motion (130 degrees) by 6 weeks to 3 months and returned to high impact activity levels, including basketball and running.”
“During ESSKA, Konrad Slynarski, M.D., Ph.D., of Lekmed Szpital in Warsaw, Poland presented his experience treating patients with early OA associated with a repetitive overload condition, such as degenerative meniscus, cartilage defects, and bone marrow edema. Eighteen consecutive patients were enrolled and achieved improvement in WOMAC pain scores from 53 ± 15 at baseline to 19 ± 15 at six months (p<0.001).”
“These are very promising results from a study that uniquely considered early OA, such as degenerative meniscal pathology and cartilage changes, in the included population,” explained Dr. Slynarski. “Patients with a degenerative meniscus and early OA often experience a recurrence of symptoms only months after meniscectomy, and now they have a pre-arthroplasty treatment option to consider.”
“In a third presentation, Priv. Doz. Dr. med. Christoph Becher, a surgeon with the ATOS Klinik Heidelberg and an Associate Professor at Hannover Medical School, revealed data from an in vitro biomechanics study demonstrating that the 13 kg of unloading by the extra-capsular absorber reduces peak contact pressure by up to 30%.”
Dr. Smigielski told OTW, “The Atlas System is a next generation, unicompartmental joint unloader based on eight years of clinical experience. It is a reversible, pre-arthroplasty procedure targeting 35-60 year olds with early to moderate knee osteoarthritis. Target patients for Atlas are often already known in surgical practices, having progressed to early osteoarthritis after previous cartilage, meniscus, or ACL procedures.”
“Many surgeons, now convinced of joint unloading as a standalone treatment, are now interested in studying the effect of unloading in combination with cartilage regeneration procedures.”

Read More

Technology, Startup News, Career Advice & More

Archives

Pin It on Pinterest

Menu